$1.56
chg
0.00 (0.00%)
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
1.16
52 wk hi
5.48
Cash
$119.1M
Burn Rate (Qtr)
$16.3M
Mkt Cap
$67.4m
Avg Volume
96,889
*cash/burn updated:
Q1 '22
Drug Pipeline
Click on drug name or indication to see upcoming trial info, prior data, and more general information.
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
GMTX
Company Profile
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Recent Posts
See what the community is saying - click to see full post.